NEW YORK (GenomeWeb News) – Bioheart, a Sunrise, Fla.-based developer of stem cell therapies for cardiovascular diseases, today said that it has entered into a global distribution and OEM pact for Life Technologies to sell the firm’s myoblast cell-based research products to life science researchers.
Bioheart said that the myoblast products will complement Life Technologies’ current portfolio of reagents for isolating, characterizing, expanding, and differentiating stem cells.
“This distribution agreement will give us access to the research community and will expand the number of therapeutic applications under development with this type of cell,” Bioheart Chairman, CEO, and CTO Howard Leonhardt said in a statement.
Financial terms of the agreement were not disclosed.